Several brokerages have updated their recommendations and price targets on shares of Mallinckrodt PLC (NYSE: MNK) in the last few weeks:

  • 10/6/2017 – Mallinckrodt PLC was given a new $70.00 price target on by analysts at UBS AG. They now have a “buy” rating on the stock.
  • 10/6/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $60.00 price target on the stock.
  • 10/6/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Stifel Nicolaus.
  • 10/5/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $67.00 price target on the stock.
  • 10/4/2017 – Mallinckrodt PLC was downgraded by analysts at Canaccord Genuity from a “buy” rating to a “hold” rating. They now have a $40.00 price target on the stock, down previously from $77.00.
  • 10/2/2017 – Mallinckrodt PLC was given a new $52.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 10/2/2017 – Mallinckrodt PLC was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 9/28/2017 – Mallinckrodt PLC is now covered by analysts at Goldman Sachs Group, Inc. (The). They set a “buy” rating and a $55.00 price target on the stock.
  • 9/19/2017 – Mallinckrodt PLC had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $70.00 to $48.00.
  • 9/15/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $67.00 price target on the stock.
  • 9/14/2017 – Mallinckrodt PLC had its price target lowered by analysts at Citigroup Inc. to $45.00. They now have a “buy” rating on the stock.
  • 9/14/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a $45.00 price target on the stock, down previously from $56.00.
  • 9/13/2017 – Mallinckrodt PLC was downgraded by analysts at Mizuho from a “buy” rating to a “neutral” rating. They now have a $40.00 price target on the stock, down previously from $70.00.
  • 9/6/2017 – Mallinckrodt PLC was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $40.00 price target on the stock, down previously from $65.00.
  • 9/6/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $70.00 price target on the stock.
  • 9/6/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $85.00 price target on the stock.
  • 9/6/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $70.00 price target on the stock.
  • 9/5/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $52.00 price target on the stock.
  • 9/1/2017 – Mallinckrodt PLC was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/25/2017 – Mallinckrodt PLC was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 8/25/2017 – Mallinckrodt PLC had its price target lowered by analysts at Jefferies Group LLC from $70.00 to $60.00. They now have a “buy” rating on the stock.
  • 8/18/2017 – Mallinckrodt PLC was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.

Shares of Mallinckrodt PLC (MNK) traded down 2.69% on Thursday, hitting $34.73. The stock had a trading volume of 1,509,040 shares. The firm’s 50 day moving average is $36.53 and its 200-day moving average is $41.60. Mallinckrodt PLC has a one year low of $33.61 and a one year high of $68.43. The stock’s market capitalization is $3.37 billion.

Mallinckrodt PLC (NYSE:MNK) last released its earnings results on Tuesday, August 8th. The company reported $1.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.73 by $0.12. Mallinckrodt PLC had a return on equity of 15.28% and a net margin of 12.64%. The business had revenue of $824.50 million for the quarter, compared to analyst estimates of $829.56 million. During the same quarter in the prior year, the company posted $2.03 earnings per share. Mallinckrodt PLC’s revenue was down 4.9% on a year-over-year basis. Equities research analysts expect that Mallinckrodt PLC will post $7.40 earnings per share for the current fiscal year.

In related news, insider Meredith B. Fischer bought 1,280 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were acquired at an average price of $39.63 per share, for a total transaction of $50,726.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.77% of the company’s stock.

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.

Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with MarketBeat.com's FREE daily email newsletter.